US Stock Market Movement: Moderna Plunged on October 27 Due to Rating Downgrade, High Valuation, and Cooling Vaccine Expectations

Interpretation of Moderna's Stock Plunge on October 27

Keywords: Downgraded Rating, High Valuation, Cooling Vaccine Expectations

1. On October 27, William Blair downgraded Moderna's rating from "Outperform" to "Market Perform," stating that after a sharp rise in the share price, the valuation already reflects a high success expectation for the expansion of cancer vaccine indications, thus suppressing stock performance.

2. On October 24, Moderna and Merck released detailed Phase III data for the melanoma vaccine, showing a 42% reduction in risk of recurrence or death, but overall survival data has not yet been released. Against the backdrop of substantial share price increases and high investor expectations this year, clinical benefit and broader commercial prospects remain under scrutiny, continuing to pressure the stock to pull back.

(Disclaimer: This content is summarized from public information collected via AI technology for reference only and does not constitute investment advice.)